A Randomized, Double-Masked, Fellow-Eye Comparison Of The Safety And Efficacy Of 0.2 And 0.5 µg/Day Fluocinolone Acetonide Intravitreal Insert To Sham Injection In Subjects With Bilateral Geographic Atrophy Due To AMD

Trial Profile

A Randomized, Double-Masked, Fellow-Eye Comparison Of The Safety And Efficacy Of 0.2 And 0.5 µg/Day Fluocinolone Acetonide Intravitreal Insert To Sham Injection In Subjects With Bilateral Geographic Atrophy Due To AMD

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2015

At a glance

  • Drugs Fluocinolone acetonide (Primary)
  • Indications Dry age-related macular degeneration
  • Focus Therapeutic Use
  • Sponsors Alimera Sciences
  • Most Recent Events

    • 28 May 2015 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov record.
    • 16 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top